Taiwan Resonant Waves Research Corp.

About Us

Taiwan Resonant Waves Research Corp. (TRWR) was founded in 2009 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.

There is unlimited promise in the application of Bioresonant Waves in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology(MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes. Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.

Great news! Fast Track for Clinical Trial Program has been approved by the Department of Industrial Technology of the Ministry of Economic Affairs (MOEA).

After 7 years of hard work and perseverance, our proprietary non-invasive, electroceutical technology for treating and alleviating symptoms associated with type 2 diabetes has been approved by MOEA for R&D subsidies.

Taiwan Resonant Waves Research Corp. has been approved by Taiwan Food and Drug Administration (TFDA) to commence clinical trials.

Our randomized, double-blind trial is underway at National Taiwan University Hospital, National Cheng Kung University Hospital, and two other medical facilities. Under the investigative leadership of 20 medical professionals, the study is expected to be completed in 2018 and potentially become the world’s first non-invasive electronic medical device used to alleviate symptoms associated with type 2 diabetes.

Good news! Taiwan Resonant Waves Research Corp. (TRWR) has acquired the US patent for diabetes glucagon mitigation using an electrical energy wave generator.

In mid-2016, we officially acquired the US patent for diabetes glucagon mitigation using an electrical energy wave generator, and have begun patent applications for this technology in 12 other countries. In addition, TRWR has obtained 11 patents in the field of electroceutical technology development around the world.

Experimental Testing, Case Studies, Clinical Trials

Research

Research and development of new indications for Microcurrent Electrical Nerve Stimulation technology (MENS) is based on our proprietary, a non-invasive MENS device. By delivering a patented electric field we developed, it tunes to a specific frequencies combination to improve disease management.

Initial MENS technology adjustments were conducted using animal or cell models for optimization and safety verification, followed by repeated testing of the efficacy of the frequencies combination through subsequent case studies and clinical trials. Results from these studies can serve as a basis for future development of a new indication of MENS technology.

About Us

News

Great news! Fast Track for Clinical Trial Program has been approved by the Department of Industrial Technology of the Ministry of Economic Affairs (MOEA).

Taiwan Resonant Waves Research Corp. has been approved by Taiwan Food and Drug Administration (TFDA) to commence clinical trials.

Good news! Taiwan Resonant Waves Research Corp. (TRWR) has acquired the US patent for diabetes glucagon mitigation using an electrical energy wave generator.

Research

Research and development of new indications for Microcurrent Electrical Nerve Stimulation technology (MENS) is based on our proprietary, a non-invasive MENS device. By delivering a patented electric field we developed, it tunes to a specific frequencies combination to improve disease management.

Research

Patent

Clinical Trials

Contact us

+886-2-2729-5800

trwr2011a@gmail.com

Social Network